PDCD1 and non-small cell lung carcinoma: With the introduction of immunotherapy, the availability of therapeutic options in metastatic NSCLC has rapidly expanded, including programmed cell death protein-1 (PD 1)/programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors [1,2].